by Harriet Boyd | Feb 2024 | Press Releases
Isogenica is proud to announce two new Non-Executive Directors Isogenica is pleased to welcome both Paul Clewlow and Trevor Phillips as our new Non-Executive Directors to the team. Paul and Trevor will play a crucial role in providing independent oversight,...
by Harriet Boyd | Nov 2023 | Press Releases
Isogenica announces two Pioneering Collaborations with an Antibody Research and License Agreement, and an Asset Evaluation Deal Isogenica, a leading innovator in VHH antibodies, is proud to unveil two significant collaborations using its synthetic VHH technology,...
by Harriet Boyd | Jul 2023 | Press Releases
University of Leicester strikes partnership with biotech experts Isogenica to develop personalised cancer treatments Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech...
by Harriet Boyd | Mar 2023 | Press Releases
Isogenica and Frederick National Laboratory for Cancer Research add two more projects to their contractual relationship Announcing a further collaboration with the Frederick National Laboratory for Cancer Research The relationship between Isogenica and...
by Harriet Boyd | Jan 2023 | Press Releases
Arvinas teams up with Isogenica using our CIS display technology to expand their PROTAC® platform Announcing a new collaboration with Arvinas Isogenica is pleased to announce a technology license agreement with Arvinas, who will leverage Isogenica’s CIS Display...
by Philippa Shelton | Nov 2022 | Press Releases, Welcome
Isogenica and Frederick National Laboratory for Cancer Research team up to discover novel antibody therapeutics Announcing a new collaboration with the Frederick National Laboratory for Cancer Research UK-based antibody engineering experts Isogenica are proud...